Autologous Serum - Endoret - PRGF
ENDORET technology based on regenerative medicine using eye plasma.
Regenerative medicine is currently revolutionising the field of ophthalmology and is an important area of study both now and for the future.
Nowadays, it is possible to cure diseases without invasive treatment, and regenerate damaged tissues, etc., thanks to the advances in technology which are currently being researched, such as the case of the extremely interesting latest-generation autologous serum technology:
Endoret (PRGF). This technology, which was implemented at ICO in 2015, is based on using the patient’s own plasma to treat the ocular surface and stimulate tissue regeneration.
What is Endoret (PRGF) technology?
Endoret (PRGF) is a biomedical technology which enables us to use the patient’s own plasma for treatment. This plasma, which is rich in growth factors and other proteins involved in repairing the body’s tissues, stimulates ocular-surface regeneration, increases eye lubrication and, as a result, helps improve patients’ quality of life.
When do we recommend autologous serum - Endoret?
Many patients who come to our surgery have epithelial defects, dry eye, allergies and erosions which are usually treated with artificial tears. However, when they are severe, persistent cases and artificial eye drops are not enough or have led to ulcers or surgery, we recommend that patients turn to their own blood to create a personalised eye drop (latest-generation autologous serum) using Endoret (PRGF) technology, thereby reducing the risk of fibrosis and corneal scars from forming. It is a quick, effective treatment which usually gives excellent results.
Benefits of Endoret (PRGF) latest-generation autologous serum
- Safely regenerates the ocular-surface tissues.
- Reduces inflammation.
- Reduces pain.
- Protects from the risk of fibrosis and corneal scars forming, favouring a clear cornea.
- Increases the ocular-surface tissue quality.
- Improves lubrication and makes it more natural.
- Reduces symptoms.
- Reduces the need for corticosteroids and ciclosporin.
- It is given to the patient as a single dose, and can be used anywhere, at any time.
The Ocular Surface Unit is available to answer any questions you may have. The Ocular Surface Unit is made up of internationally renowned experts with extensive experience, including Dr Susana Duch, Dr Magela Garat, and Dr Cristina Vendrell, who runs the Dry Eye Area.